India's pharma stocks fall after Trump outlines steep tariffs on generic drug imports
BUZZ-India's pharma stocks fall after Trump outlines steep tariffs on generic drug imports Updates
** Nifty Pharma Index .NIPHARM down 1.52%
** Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS, Cipla CIPL.NS, Lupin LUPN.NS, Glenmark GLEN.NS, Dr Reddy's REDY.NS and Zydus ZYDU.NS decline 1.2%-3.9%, with Lupin the worst hit
** Trump says imported generic drugs will remain tariff-free for two years from August 1, before tariffs increase to 100% for one year and 200% thereafter
** "The headline is negative, but key details around implementation, legal challenges, exemptions and final scope remain unclear ... We would view it more as a policy signal than a quantifiable earnings event" - Niharika Agarwal, analyst at Nirmal Bang
** PL Capital says existing U.S. facilities may partly cushion impact, but two years is too short to relocate entire generic pharma value chain
** Motilal Oswal says tariff implementation remains uncertain, with major impact due from August 2028, near end of Trump's term
(Reporting by Abhinav Parmar in Bengaluru)
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma Gets Tax Order Confirming Total Disputed Amount 46 Million Rupees
India's Aurobindo Pharma falls after US FDA flags observation at Telangana facility
Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
Brief: Aurobindo Pharma Gets USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol
Brief: Aurobindo Pharma Says US FDA Inspected Unit-IV Of Apitoria Pharma From September 7 To September 11